Showing results (31-40 of 65) with videos related to

Sort By:
Pageof 7
Bone Marrow Transplantation|April 10, 2019
Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registryAnna Lübking, Arta Dreimane, Fredrik Sandin, et al.
Oncoimmunology|August 18, 2022
IFNγ directly counteracts imatinib-induced apoptosis of primary human CD34+ CML stem/progenitor cells potentially through the upregulation of multiple key survival factorsDorina Ujvari, Alena Malyukova, Ana Zovko, et al.
European Journal of Haematology|July 19, 2016
Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era - a report from the Swedish CML registerStina Söderlund, Torsten Dahlén, Fredrik Sandin, et al.
British Journal of Haematology|March 31, 2015
Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor eraNiklas Gunnarsson, Leif Stenke, Martin Höglund, et al.
American Journal of Hematology|January 11, 2022
Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register studyTorsten Dahlén, Gustaf Edgren, Per Ljungman, et al.
British Journal of Haematology|August 30, 2002
Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase--a report from the Swedish CML GroupUlla Axdorph, Leif Stenke, Gunnar Grimfors, et al.
Biochemical and Biophysical Research Communications|June 18, 2017
Leukotriene signaling via ALOX5 and cysteinyl leukotriene receptor 1 is dispensable for in vitro growth of CD34+CD38- stem and progenitor cells in chronic myeloid leukemiaMonika Dolinska, Alexandre Piccini, Wan Man Wong, et al.
Blood|January 27, 2017
Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CMLRebecca Warfvinge, Linda Geironson, Mikael N E Sommarin, et al.
British Journal of Pharmacology|June 25, 2022
The tyrosine kinase inhibitor nilotinib targets the discoidin domain receptor DDR2 in calcific aortic valve stenosisMiguel Carracedo, Sven-Christian Pawelzik, Gonzalo Artiach, et al.
British Journal of Haematology|March 30, 2021
Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registryHjalmar Flygt, Fredrik Sandin, Torsten Dahlén, et al.
Pageof 7